The State of ADCs: Where the Market Stands, and Where It’s Headed
The ADC 2025 Landscape Review delivers a comprehensive, data-driven analysis of the antibody drug conjugate space, capturing the most important scientific, clinical, commercial, regulatory, and intellectual property developments from 2025.
Across traditional and next-generation modalities, this report highlights where momentum is accelerating, where saturation is setting in, and where genuine differentiation is emerging.
With regulatory milestones approaching, deal-making strategies shifting, and innovation increasingly defined by payload selection, target choice, and IP positioning, this review equips you with the context needed to prioritise assets, partners, and technologies in a rapidly maturing market.
Download your free copy today.
What’s Inside?
The Drug Landscape
An in-depth look at the expanding ADC pipeline, covering growth by modality, drug status changes, target selection trends, payload technologies, and the rise of novel conjugate formats that are reshaping competitive differentiation.
The Trial Landscape
A detailed analysis of global ADC clinical activity, including trial volume, phase progression, recruitment trends, discontinuations, and the ADCs driving the highest levels of clinical momentum.
The Commercial Landscape
A review of deal-making and company activity, exploring how M&A, licensing, and financing trends have shifted toward later-stage, de-risked assets, alongside insights into geographic and corporate leadership in ADC development.
Regulatory Announcements
Key regulatory updates from global authorities, highlighting new approvals, breakthrough designations, and expedited pathways that are shaping near-term commercial and clinical opportunities.
The Future of ADCs
A forward-looking assessment of emerging targets, payload mechanisms, and modality innovation, outlining where scientific investment is concentrating and which approaches are most likely to define the next wave of ADC value creation.
Patents Landscape
A comprehensive review of the ADC intellectual property environment, examining filing trends, geographic dynamics, grant quality, ownership concentration, and how next-generation constructs are extending exclusivity beyond first-generation patents.
Previous ADC Landscape Reviews
ADC H1 2025 Landscape Review
ADC 2024 Landscape Review
ADC H1 2024 Landscape Review
You May Also Be Interested In…
Learn More About ADC
- The Most Comprehensive Way to Search the ADC Drug Development Landscape: Unique search ontologies based on ADC drug and trial characteristics
- Market Leading Approach to ADC Preclinical & Clinical Data Curation: Manual curation of key ADC research and development data points by ADC research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search ADC company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
